Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from BioCryst ( (BCRX) ).
On June 27, 2025, BioCryst Pharmaceuticals entered into a Stock Purchase Agreement to sell its equity interests in BioCryst Ireland to Neopharmed Gentili S.p.A. for $250 million, with potential additional payments based on revenue milestones. This transaction, expected to close in October 2025, will involve amendments to existing intellectual property agreements and establish BioCryst as the exclusive supplier of ORLADEYO® to the company, impacting BioCryst’s operations and market positioning in Europe.
The most recent analyst rating on (BCRX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s stock reflects a mixed outlook. Positive earnings call sentiment and strategic corporate events contribute to a favorable outlook, but financial instability and negative technical indicators pose significant risks. Future growth depends on continued revenue expansion and financial management.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals, Inc. is a pharmaceutical company involved in the development and commercialization of novel oral and small-molecule medicines. The company focuses on rare diseases, with ORLADEYO® being one of its primary products, particularly in the European market.
Average Trading Volume: 4,634,481
Technical Sentiment Signal: Buy
Current Market Cap: $1.96B
For a thorough assessment of BCRX stock, go to TipRanks’ Stock Analysis page.